Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.50
ACUR's Cash to Debt is ranked higher than
71% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ACUR: 1.50 )
ACUR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.5

Equity to Asset 0.39
ACUR's Equity to Asset is ranked higher than
54% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ACUR: 0.39 )
ACUR' s 10-Year Equity to Asset Range
Min: -7.86   Max: 0.97
Current: 0.39

-7.86
0.97
F-Score: 3
Z-Score: -26.20
M-Score: 36.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5145.91
ACUR's Operating margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. ACUR: -5145.91 )
ACUR' s 10-Year Operating margin (%) Range
Min: -11455.28   Max: 51.47
Current: -5145.91

-11455.28
51.47
Net-margin (%) -5420.23
ACUR's Net-margin (%) is ranked lower than
55% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. ACUR: -5420.23 )
ACUR' s 10-Year Net-margin (%) Range
Min: -11301.63   Max: 50.74
Current: -5420.23

-11301.63
50.74
ROE (%) -99.52
ACUR's ROE (%) is ranked lower than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. ACUR: -99.52 )
ACUR' s 10-Year ROE (%) Range
Min: -61.03   Max: 51.89
Current: -99.52

-61.03
51.89
ROA (%) -59.84
ACUR's ROA (%) is ranked lower than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. ACUR: -59.84 )
ACUR' s 10-Year ROA (%) Range
Min: -1207.97   Max: 33.14
Current: -59.84

-1207.97
33.14
ROC (Joel Greenblatt) (%) -1260.24
ACUR's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. ACUR: -1260.24 )
ACUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1243.6   Max: 1569.92
Current: -1260.24

-1243.6
1569.92
Revenue Growth (3Y)(%) -100.00
ACUR's Revenue Growth (3Y)(%) is ranked lower than
54% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ACUR: -100.00 )
ACUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 27.3
Current: -100

0
27.3
EBITDA Growth (3Y)(%) 2.40
ACUR's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ACUR: 2.40 )
ACUR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -60.2   Max: 144.4
Current: 2.4

-60.2
144.4
EPS Growth (3Y)(%) 2.40
ACUR's EPS Growth (3Y)(%) is ranked higher than
72% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ACUR: 2.40 )
ACUR' s 10-Year EPS Growth (3Y)(%) Range
Min: -84.9   Max: 56.5
Current: 2.4

-84.9
56.5
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ACUR Guru Trades in

ACUR Guru Trades in

Q2 2014

ACUR Guru Trades in Q2 2014

Jim Simons 12,700 sh (New)
» More
Q3 2014

ACUR Guru Trades in Q3 2014

Jim Simons 44,900 sh (+253.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
ACUR's P/B is ranked higher than
74% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. ACUR: 3.30 )
ACUR' s 10-Year P/B Range
Min: 0.62   Max: 15.82
Current: 3.3

0.62
15.82
P/S 99.00
ACUR's P/S is ranked higher than
50% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. ACUR: 99.00 )
ACUR' s 10-Year P/S Range
Min: 1.07   Max: 249
Current: 99

1.07
249
EV-to-EBIT -1.56
ACUR's EV-to-EBIT is ranked higher than
61% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. ACUR: -1.56 )
ACUR' s 10-Year EV-to-EBIT Range
Min: -45.3   Max: 63
Current: -1.56

-45.3
63
Current Ratio 5.32
ACUR's Current Ratio is ranked higher than
87% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ACUR: 5.32 )
ACUR' s 10-Year Current Ratio Range
Min: 0.02   Max: 68.17
Current: 5.32

0.02
68.17
Quick Ratio 5.19
ACUR's Quick Ratio is ranked higher than
88% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. ACUR: 5.19 )
ACUR' s 10-Year Quick Ratio Range
Min: 0.01   Max: 68.17
Current: 5.19

0.01
68.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.67
ACUR's Price/Net Cash is ranked higher than
93% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACUR: 8.67 )
ACUR' s 10-Year Price/Net Cash Range
Min: 2.81   Max: 112
Current: 8.67

2.81
112
Price/Net Current Asset Value 8.67
ACUR's Price/Net Current Asset Value is ranked higher than
89% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACUR: 8.67 )
ACUR' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 112
Current: 8.67

2.76
112
Price/Tangible Book 4.73
ACUR's Price/Tangible Book is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. ACUR: 4.73 )
ACUR' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 80
Current: 4.73

2.64
80
Earnings Yield (Greenblatt) -64.10
ACUR's Earnings Yield (Greenblatt) is ranked lower than
54% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ACUR: -64.10 )
ACUR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 19720.9
Current: -64.1

1.6
19720.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HD4A.Germany,
Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints Oct 15 2014 
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 
American Honda Reports 2008 Annual and December Monthly Sales Jan 05 2009 
Acura Announces December and 2008 Year-End Sales Results Jan 05 2009 

More From Other Websites
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Dec 23 2014
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy Dec 23 2014
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy Dec 23 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K/A, Change in Directors or Principal Officers Dec 12 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 11 2014
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations Dec 08 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Dec 08 2014
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations Dec 08 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2014
Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results Nov 03 2014
Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4,... Oct 28 2014
Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4,... Oct 28 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Oct 16 2014
Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets... Oct 16 2014
Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets... Oct 16 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Sep 29 2014
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints Sep 29 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Sep 18 2014
Impax Rytary FDA Action Date Extended by Three Months Sep 18 2014
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK